Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Even Market-Neutral Funds Couldn’t Escape the AI Slump in October Julie Segal It’s Biopharma or Bust for the IPO Market Stephen Taub Your Alternatives Need an Alternative Sponsored by iM Global Partner